Skip to main content

Table 1 Clinical and pathological patient characteristics of the TCGA and CPC-GENE cohorts

From: Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations

  Entire cohort CR/IDC positive CR/IDC negative
TCGA CPC-GENE TCGA CPC-GENE TCGA CPC-GENE
Mean (IQR) or N (%) Mean (IQR) or N (%) Mean (IQR) or N (%)
Number 260 (100%) 199 (100%) 80 (31%) 76 (38%) 180 (69%) 123 (62%)
Age (years) 60 (56–66) 61 (57–66) 61 (57–66) 61 (58–66) 60 (55–70) 61 (57–64)
PSA (ng/mL) 10 (5.1–11) 7.6 (4.8–9.3) 12 (6.4–15) 8.1 (4.9–10) 9.5 (4.6–9.7) 7.3 (4.8–9.1)
GS
 3 + 3 96 (37%) 69 (35%) 0 0 96 (53%) 69 (56%)
 3 + 4 78 (30%) 95 (48%) 27 (34%) 44 (58%) 51 (28%) 51 (41%)
 4 + 3 39 (15%) 25 (12%) 22 (27%) 22 (29%) 17 (10%) 3 (3%)
 8 19 (7.3%) 9 (4%) 17 (21%) 9 (12%) 2 (1%) 0
 9–10 28 (11%) 1 (1%) 14 (18%) 1 (1%) 14 (8%) 0
pT stage
 T2 112 (43%) 84 (42%) 20 (25%) 20 (26%) 92 (51%) 64 (52%)
 T3a 80 (31%) 58 (29%) 28 (35%) 26 (35%) 52 (29%) 32 (26%)
 T3b 55 (21%) 15 (8%) 31 (39%) 10 (13%) 24 (13%) 5 (4%)
 T4 4 (2%) 0 1 (1%) 0 3 (2%) 0
 Tx 9 (3%) 42 (21%) 0 20 (26%) 9 (5%) 22 (18%)
  1. GS Gleason score, PSA Prostate Specific Antigen